Seoul Clinical Laboratories

Seoul Clinical Laboratories, a for-profit South Korean clinical laboratory and diagnostic testing provider headquartered in Yongin-si, Gyeonggi-do, operates as a prime contractor delivering reference laboratory testing services and clinical diagnostic support to U.S. military healthcare facilities in the Pacific region, with 100 percent of its federal award footprint in prime contracts and no subcontract exposure.

The vendor's customer base concentrates heavily on Department of Defense military medical operations in South Korea. The top five customer agencies by award count (97% coverage) are the Department of the Navy Installations Command (80 awards, $30 thousand combined potential value), the Department of the Air Force Pacific Air Forces (51 awards, $5.6 million), the Department of the Army Medical Command (31 awards, $34.9 million), the Defense Health Agency (8 awards, $1.5 million), and the Department of the Army (2 awards). Ranking by potential value reveals a different concentration: the Army Medical Command anchors the portfolio at $34.9 million across 31 awards, followed by Pacific Air Forces at $5.6 million across 51 awards — a tension between order frequency and dollar magnitude driven by the Navy's high-volume, low-value task orders against bench-stock vehicle N6264907A0041. The 178 total awards carry combined potential value of $44.1 million, with $17.2 million (39 percent) obligated to date.

Seoul Clinical Laboratories' work spans three parent vehicle platforms. The Indefinite Delivery Contract N6264907A0041 (Navy) anchors 55 task orders with $28 thousand combined potential value. The Blanket Purchase Agreement W90VN621A0006 (Army) carries 50 task orders valued at $5.4 million and represents Seoul's largest single vehicle by dollar value. The Blanket Purchase Agreement N6264914A0001 (Navy) has placed 25 task orders for $2 thousand. Two additional Army IDCs — W81K0214D0001 (9 task orders, $182 thousand) and W81K0219D0008 (6 task orders, $273 thousand) — round out the core platform footprint. The vendor also holds a newly awarded Defense Health Agency multiple-award BPA (award date March 1, 2026, ceiling $200 thousand, completion February 28, 2031) for reference laboratory testing services at Osan Air Base, Republic of Korea.

Representative capability work includes a $597,434.80 single-award indefinite-delivery contract with the Defense Health Agency (awarded September 6, 2024, completion September 5, 2029) for clinical laboratory testing services at Brian D. Allgood Army Community Hospital (BDAACH), Korea, with three delivery orders issued to date ($24,452.64 base-period task order, $31,769.37 May 2025 task order, $25,194.92 September 2025 task order). Seoul also delivered a $3.1 million COVID-19 diagnostic testing delivery order with the Department of the Army Medical Command (October 2021 award, completion June 2022, later terminated for government convenience). Month-to-month BPA calls under the Army's W90VN621A0006 vehicle span pathology testing, manual clinical laboratory actions, and general blood-work services in the $589 to $1,468 per-call range, issued consistently from 2021 through 2026. All awarded work carries no set-aside designation and is firm fixed price.

Activity has run flat to modest decline: 14 awards in 2022 and 2024, 13 in 2023, 9 in 2025, and 2 in early 2026. Only one award (ceiling $25 thousand) completes within the next twenty-four months, indicating minimal near-term recompete exposure. Seoul's NAICS footprint is concentrated in Medical Laboratories (157 awards) with smaller exposure to Diagnostic Imaging Centers (10 awards) and Testing Laboratories and Services (6 awards). Place of performance is uniformly South Korea, reflecting the vendor's role as an embedded clinical laboratory provider for U.S. military medical facilities in the Pacific region. The vendor registered in SAM.gov in 2006 and operates as a mega-reference laboratory serving thousands of Korean healthcare facilities alongside its dedicated U.S. military customer base.